Receptor endocytosis counteracts the development of opioid tolerance

Thomas Koch, Antje Widera, Katharina Bartzsch, Stefan Schulz, Lars-Ove Brandenburg, Nicole Wundrack, Andrea Beyer, Gisela Grecksch, and Volker Höllt*

Department of Pharmacology and Toxicology, Otto-von-Guericke University, 39120 Magdeburg, Germany
Running Title: Endocytosis counteracts receptor desensitization

Corresponding author: Thomas Koch, Department of Pharmacology and Toxicology, Otto-von-Guericke University, 39120 Magdeburg, Leipziger Str. 44, Germany. Phone +49-391-671-5372, FAX: +49-391-671-5869,
E-mail: Thomas.Koch@Medizin.Uni-Magdeburg.de

Number of text pages: 33
Number of tables: 1
Number of figures: 5
Number of references: 31
Number of words in the abstract: 250
Number of words in the introduction: 691
Number of words in the discussion: 1225

Abbreviations: DAMGO, [D-Ala², Me Phe⁴, Gly⁵]enkephalin; HEK 293, human embryonic kidney 293; MOR1, rat µ-opioid-receptor
Abstract

In contrast to endogenous opioids, the highly addictive drug morphine activates the μ-opioid receptor without causing its rapid endocytosis. Recently, it has been reported that coapplication of low concentrations of [D-Ala²-MePhe⁴-Gly⁵-ol] enkephalin (DAMGO) facilitates the ability of morphine to stimulate μ-opioid receptor endocytosis and prevents the development of morphine tolerance in rats. To investigate the clinical relevance of this finding for analgesic therapy the endocytotic efficacies of a series of clinically used opioids were determined and the effect of a combination of these drugs with morphine on the μ-opioid receptor endocytosis in receptor expressing HEK293 cells quantified. Combination of morphine and opioid drugs with high endocytotic efficacies (e.g. DAMGO, etonitazene, sufentanil, β-endorphin, piritramide, or methadone) did not result in a facilitation of morphine-mediated endocytosis but rather in a decrease of the receptor endocytosis mediated by the tested opioid drugs. These findings demonstrate a partial agonistic effect of morphine on the agonist-induced receptor endocytosis. Moreover, we demonstrated that the endocytotic potencies of opioid drugs are negatively correlated with their ability to cause receptor desensitization and opioid tolerance in HEK293 cells. These results strongly support the hypothesis that μ-opioid receptor endocytosis counteracts receptor desensitization and opioid tolerance by inducing fast receptor reactivation and recycling. In addition it is shown that agonist-induced receptor endocytosis facilitates the compensatory upregulation of the cAMP pathway, a cellular hallmark of opioid withdrawal. Our findings suggest that opioids with high endocytotic efficacies might cause reduced opioid tolerance but can facilitate compensatory mechanisms resulting in an enhanced opioid dependence.
**Introduction**

*In vitro* and *in vivo* studies revealed that on the cellular level chronic opioid treatment leads to a rapid receptor desensitization with reduction of agonist response followed by internalization of receptors. An important mechanism of µ-opioid receptor desensitization is the phosphorylation of intracellular receptor domains by G protein-coupled receptor kinases (GRKs) or second messenger-regulated protein kinases, such as Ca$^{2+}$/calmodulin-dependent protein kinase II (Koch *et al.*, 2000; Koch *et al.*, 1997; Pak *et al.*, 1997; Wolf *et al.*, 1999). After phosphorylation of Ser/Thr residues on the C-terminus of the receptor, arrestins are frequently recruited to the plasma membrane where they accelerate uncoupling of the receptor from the G-protein and facilitate receptor endocytosis by serving as scaffolding proteins that bind to clathrin (Ferguson *et al.*, 1996; Goodman *et al.*, 1996). Internalized receptors can be sorted either to a degradative pathway or to a recycling pathway returning active receptors to the plasma membrane (von Zastrow *et al.*, 2003). Thus the regulation of µ-opioid receptor endocytosis and trafficking might play a critical role in the development of opioid tolerance and dependence.

While endogenous opioids as well as the synthetic peptide DAMGO promotes the rapid endocytosis of µ-opioid receptors, the highly addictive drug morphine fails to promote detectable endocytosis, even when present at high concentrations. Recently it has been reported, that the coapplication of a low concentration of the µ-agonist DAMGO can facilitate the morphine-induced µ-opioid receptor endocytosis and results in a loss of morphine tolerance development in rats (He *et al.*, 2002). This intriguing finding might have implications for the analgesic therapy, because coapplication of morphine with a receptor-internalizing opioid agonist should induce less opioid tolerance than morphine alone. Therefore in the present study we
investigated the effect of a coapplication of low doses of receptor-internalizing and clinically relevant opioids on the morphine-induced µ-opioid receptor endocytosis.

It has been demonstrated in numerous studies that agonist-induced µ-opioid receptor endocytosis can reduce the development of opioid tolerance (Koch et al., 2004; He et al., 2002; Koch et al., 2001; Whistler et al., 1999; Koch et al., 1998) but the mechanisms that are responsible for the protection against opioid tolerance by receptor endocytosis are still controversially discussed. One hypothesis is that µ-opioid receptor endocytosis leads to a rapid downregulation of receptor signaling (Whistler et al., 1999). For example, agonists that do not induce endocytosis like morphine were predicted to have a longer duration of action, leading to greater compensatory effects (e.g. adenylate cyclase superactivation) and thus to greater tolerance and addiction (Whistler et al., 1999). Agonists that drive receptor endocytosis should lead to a fast receptor uncoupling from the G-protein and therefore to a lesser extent of compensatory effects and tolerance (He et al., 2002; Whistler et al., 1999). However, recent studies have demonstrated that endocytozed µ-opioid receptors are predominantly and rapidly recycled to the cell surface in a reactivated state (El Kouhen et al., 1999; Ferguson et al., 1998; Koch et al., 2001; Koch et al., 1998; Law et al., 2000). These findings led to a revision of the prevailing hypothesis and suggest that µ-opioid receptor endocytosis is an important mechanism to ensure that desensitized and internalized receptors are rapidly recycled to the cell surface in an active form maintaining receptor signaling and reducing receptor desensitization and tolerance development (Koch et al., 2001; Finn and Whistler, 2001; Koch et al., 1998). In this revised model, non-internalizing agonists like morphine cause an accumulation of desensitized receptors in the plasma membrane resulting in greater opioid tolerance (Koch et al., 2004; Schulz et al., 2004; Koch et al., 2001).

To further elucidate the role of endocytosis in the regulation of receptor signaling we analyzed the effect of µ-opioid receptor endocytosis by a large series of
predominantly used opioids on the receptor desensitization rate. We found that the
endocytotic efficacy of opioids is negatively correlated with the development of
receptor desensitization. This finding is further supported by our observation that
receptor endocytosis enhances the compensatory upregulation of adenylate cyclase
activity by reducing receptor desensitization and maintaining the receptor signaling.
These results strongly indicate that receptor endocytosis followed by receptor
recycling counteracts the development of opioid tolerance by a fast receptor
reactivation.
Materials and Methods

Drugs: Morphine was obtained from Synopharm (Barsbüttel, Germany), β-endorphin and DAMGO were obtained from Bachem (Heidelberg, Germany) and methadone was from Merck (Darmstadt, Germany). Pethidine was purchased from Aventis (Bad Soden, Germany) and etonitazene was from Novartis (Nürnberg, Germany). Hydromorphone was provided by Knoll GmbH (Uetersen, Germany), oxycodone was provided by Mundipharma (Limburg/Lahn, Germany), nortilidine was provided by Pfizer (Karlsruhe, Germany), buprenorphine was provided by Grünenthal (Aachen, Germany) and piritramide, sufentanil, and fentanyl was provided by Janssen-Cilag (Neuss, Germany). All other reagents were of analytical grade from standard commercial sources.

Epitope Tagging and Cloning of cDNA: The rat µ-opioid receptor (MOR1) was tagged at the NH₂-terminus with the HA epitope tag sequence MYPYNVPNYA using polymerase chain reaction and then subcloned into the pEAK10 expression vector (Edge Bio Systems, Gaithersburg, MD).

Generation of Cell Lines Expressing µ-Opioid Receptors: Transfection of HEK 293 cells was performed by the calcium phosphate precipitation method (Chen and Okayama, 1988). Approximately 1.5 x 10⁶ cells were transfected with 20 µg of plasmid DNA. Cells were selected in the presence of 1 µg/ml puromycin (Sigma, Deisenhofen, Germany), and resistant cells were grown in the presence of 1 µg/ml puromycin. Six clones were generated and receptor expression was monitored using saturation ligand binding assays.
Radioligand Binding Assays: Binding studies were performed on membranes prepared from stably transfected cells. The dissociation constant (K_D) and number of [³H]DAMGO binding sites (B_max) was calculated by Scatchard analysis using at least six concentrations of [³H]DAMGO in a range from 0.3 to 9 nM as previously described (Koch et al., 1998). Non-specific binding was determined as radioactivity bound in the presence of 1 µM unlabeled DAMGO.

Quantitative internalization assay: Cells were seeded at a density of 2 x 10⁵ per well and grown onto poly-L-lysine-treated 24-well plates overnight. After washing cells were preincubated with 1 µg affinity-purified rabbit anti-HA antibody for 2 h in OPTIMEM 1 (Life Technologies) at 4°C. For induction of receptor internalization cells were then treated as indicated with various doses of agonists for 60 min in OPTIMEM at 37 °C. After fixation with 4% paraformaldehyde and 0.2% picric acid in 0.1 M phosphate buffer and washing in TPBS (10 mM Tris, 10 mM phosphate buffer, 137 mM NaCl, 0.05% thimerosal, pH 7.4), cells were incubated with peroxidase-conjugated anti-rabbit antibody (1:1000, Amersham, Braunschweig, Germany) for 2 h at room temperature. Plates were developed with 250 µl of ABTS solution (Roche Molecular Biomedicals, Mannheim, Germany) at room temperature. After 10-30 min, 200 µl of the substrate solution from each well was transferred to a 96-well plate and analyzed at 405 nm using a microplate reader.

Determination of Receptor Signaling, Desensitization, and cAMP superactivation by Measurement of cAMP Accumulation: Approximately 1.5 x 10⁵ cells per well were seeded in 22 mm-twelve well dishes with DMEM Nut-F 12 medium containing 10% FCS and incubated at 37°C for 24 hours. For desensitization measurements, HEK 293 cells expressing MOR1 were either exposed or not exposed for 1 hour with receptor saturating opioid doses followed by determination of agonist-induced inhibition of forskolin-stimulated adenylate cyclase. Treatment with
25 µM forskolin (Biotrend, Köln, Germany) resulted in a five-fold increase of intracellular cAMP as compared to untreated MOR1-expressing HEK 293 cells. Maximum agonist-induced inhibition of cAMP accumulation without agonist preincubation has been defined as 100%. Receptor desensitization was measured as the decreased ability of the agonist to inhibit forskolin-stimulated adenylate cyclase activity after 1 hour of agonist treatment. For the cAMP superactivation measurements, MOR1 expressing HEK293 cells were chronically exposed to 1 µM DAMGO or 1 µM morphine for 1 h and 8 h. For agonist withdrawal, the cells were rinsed 3-times in drug free medium followed by measurement of cAMP accumulation. For the measurement of cAMP accumulation, medium was removed from individual wells and replaced by 0.5 ml serum-free RPMI medium (Seromed, Berlin, Germany) containing 25 µM forskolin or 25 µM forskolin plus receptor saturating doses of agonists. The cells were incubated at 37°C for 15 min. The reaction was terminated by removing the medium and sonicating the cells in 1 ml of ice-cold HCl/ethanol (1 volume of 1 N HCl/100 volumes of ethanol). After centrifugation, the supernatant was evaporated, the residue was dissolved in TE buffer and the cAMP content was determined using a commercially available radioimmunoassay kit (Amersham, Braunschweig, Germany). Statistical evaluation of results was carried out using ANOVA followed by Bonferroni test.
Results

Expression of HA-epitope tagged μ-opioid receptor in human embryonic kidney (HEK293) Cells: The rat μ-opioid receptor MOR1 was HA-epitope tagged, subcloned in the peak10 expression vector (Edge Biosystems, Gaithersburg, MD) and stably expressed in HEK 293 cells. From 6 stably transfected clones we selected a cell line that expressed 968 ± 7 fmol of [3H]DAMGO binding sites per milligram of membrane protein. The KD for [3H]DAMGO was 1.55 ± 0.4 nM.

Determination of opioid efficacies and potencies for receptor internalization: To determine the efficacies and potencies of various opioids to induce μ-opioid receptor endocytosis in HEK293 cells, we used an ELISA-technique to quantify the maximum agonist-induced internalization of HA-epitope tagged MORs in intact HEK293 cells (Koch et al., 2004). A maximal (50%) receptor internalization was found after 60 min of agonist treatment even with low concentrations of DAMGO (1 µM), etonitazene (10 nM), and sufentanil (10 nM) (Table 1; Fig. 1). Consistent with quantitative internalization experiments reported previously (Keith et al., 1998) the agonists β-endorphin, piritramide, methadone, and fentanyl caused partial internalization (20-30%) and only when present at high concentrations (≥10 µM). Under the same conditions morphine, nortilidine, pethidine, buprenorphine, hydromorphone, and oxycodone failed to induce significant μ-opioid receptor endocytosis even when present at high concentrations (Table 1, Fig. 1). Thus, the drugs differ in their percentage of maximal receptor internalization with the following rank order: DAMGO = sufentanil = etonitazene >> β-endorphin = piritramide > methadone = fentanyl >>>>> oxycodone > hydromorphone = buprenorphine = nortilidine = pethidine = morphine.
However, analyses of the dose-dependency of receptor endocytosis of the various agonists revealed that sufentanil and etonitazene were ≈600-fold more potent than DAMGO in promoting receptor endocytosis (EC$_{50}$ endocytosis, Table 1). On the other hand DAMGO was ≈16-fold more potent than methadone and ≈130-fold more potent than fentanyl in inducing half-maximal receptor endocytosis (Table 1). Morphine, pethidine, nortilidine, buprenorphine, hydromorphone, and oxycodone were incapable of inducing detectable receptor endocytosis even at very high concentrations (>100 µM). Thus, according to Keith et al. (Keith et al., 1998) the EC$_{50}$ for endocytosis for the non-internalizing drugs was defined to be greater than 1 mM (Table 1).

Effect of coapplication of various receptor-internalizing opioids on the morphine-induced µ-opioid receptor endocytosis in HEK293 cells: In the next step we tested three opioids with high endocytotic efficacies (e.g. DAMGO, etonitazene, and sufentanil) (Fig. 2A, B, and C) as well as three agonists with lower endocytotic efficacies (e.g. ß-endorphin, piritramide, and methadone) (Fig. 2 D, E, and F) concerning their effects on the morphine-induced receptor endocytosis. Therefore, ascending opioid concentrations of the drugs mentioned above resulting in increasing receptor endocytosis were used in combination with 1 µM morphine (Fig. 2). However, neither low nor high concentrations of the tested receptor-internalizing agonists led to an enhanced morphine-induced receptor endocytosis compared to the tested agonists alone (Fig. 2). In contrast, for all concentrations the agonist-induced endocytosis in the presence of 1 µM morphine was less than that induced by the tested agonist concentrations alone. Also coapplication of higher concentrations (5 µM and 30 µM) of morphine dose-dependently reduced the agonist-induced endocytosis of the tested agonists (data not shown). In fact, coapplication of morphine led to a decrease of the receptor internalization rate for all tested agonists,
demonstrating that morphine clearly behaves as a partial agonist for inducing receptor endocytosis (Fig. 2).

_Determination of RAVE values and internalization/signaling potency ratios for various opioids:_ By using the maximum percentage of receptor endocytosis and AC-inhibition we next calculated the RAVE (relative activity versus endocytosis) values of the tested agonists (Table 1). According to the RAVE model (Whistler et al., 1999) DAMGO was defined as having activity and endocytosis of 1 and thus a RAVE of 1. As expected and consistent with the RAVE model, similarly low RAVE values between 1 and 1.76 were calculated for agonists promoting high or partial receptor endocytosis, whereas the non-internalizing agonists revealed high RAVE values between 5 and 9.8 (Table 1).

To further investigate whether the agonist potency for induction of receptor signaling is correlated with the ability to induce receptor endocytosis the concentrations of various opioids required to achieve 50% of maximal response (EC$_{50}$) for both inhibition of cAMP accumulation and receptor endocytosis were calculated. The tested agonists exhibited inhibition of cAMP accumulation with maximal effects or efficacies ranging from 31% - 72% (Table 1). The EC$_{50}$ values for adenylate cyclase inhibition of all ligands studied were between 0.055-370 nM. When the internalization/signaling potency ratios of the EC$_{50}$ values for internalization and adenylate cyclase inhibition were compared, lowest ratios were found for the highly potent drugs etonitazene and sufentanil, 0.37 and 16.4, respectively, followed by DAMGO, ß-endorphin, and piritramide with ratios of 46, 73, and 86, respectively (Table 1). The agonists fentanyl and methadone, promoting only partial receptor internalization, revealed ratios of 620 and 909, respectively. Highest ratios (≈ 3000 -
40,000) were found for the non-internalizing drugs, nortilidine, oxycodone, pethidine, morphine, buprenorphine, and hydromorphone. The observed great differences in the internalization/signaling potency ratios between the drugs tested indicate, that the relative potency of individual agonists for promoting receptor internalization is not correlated with signaling potency and thus, is an independent functional property of opioid agonists.

Role of µ-opioid receptor endocytosis in the agonist-induced receptor desensitization: Next, we investigated if the observed differences of the opioids in promoting receptor internalization would affect the rate of agonist-induced desensitization. Receptor desensitization was measured as the decreased ability of the agonist to inhibit forskolin-stimulated adenylate cyclase activity after extended agonist pretreatment. In previous studies we have demonstrated that 1 hour of agonist pretreatment is sufficient to induce marked receptor desensitization in HEK293 cells expressing the µ-opioid receptor (Koch et al., 2004; Koch et al., 1998). Thus, in the present study HEK 293 cells expressing MOR1 were pretreated for 1 hour with receptor saturating opioid doses followed by determination of agonist-induced inhibition of forskolin-stimulated adenylate cyclase. Forskolin treatment resulted in a five-fold increase of intracellular cAMP (up to 4 pmol) as compared to untreated MOR1-expressing HEK 293 cells. Maximum agonist-induced inhibition of cAMP accumulation without agonist preincubation has been defined as 100%. As depicted in Fig. 3A, prolonged exposure (1 h) to non-internalizing agonists (e.g. buprenorphine, morphine, hydromorphone, pethidine, nortilidine, and oxycodone) resulted in strong (≈ 40 - 70%) receptor desensitization. Opioids that promote partial receptor endocytosis (e.g. fentanyl, methadone, piritramide, and ß-endorphin) revealed only ≈ 30-40% of receptor desensitization and remarkably, weakest receptor
desensitization (≈10-25%) was observed for the opioids inducing high receptor endocytosis (e.g. DAMGO, sufentanil, and etonitazene) (Fig. 3A). By using the non-parametric Spearman's test, a significant negative correlation between receptor endocytosis and desensitization was found (Fig. 3A). To further evaluate the correlation of signaling and internalization potencies and receptor desensitization we calculated the internalization/signaling potency ratios of the agonists (Table 1). In the HEK293 cell expression system we detected an almost linear and highly significant correlation between the internalization/signaling potency ratios of the tested opioids and the induced µ-opioid receptor desensitization (Fig. 3B). These results can be explained by the model that agonist-induced receptor endocytosis maintains receptor signaling during chronic agonist treatment by fast receptor recycling and reactivation. Thus we predicted that blocking of receptor recycling and reactivation by monensin would accelerate agonist-induced receptor desensitization. As expected coapplication of monensin with the receptor internalizing agonists DAMGO and methadone resulted in an enhanced receptor desensitization after 1 h of agonist treatment (Fig. 4). On the other hand monensin treatment had no effect on the desensitization of the morphine treated receptor which does not undergo endocytosis (Fig. 4). Furthermore, in control experiments monensin treatment had no effect on the adenylate cyclase activity and the functional coupling of the µ-opioid receptor (data not shown). Note that in the presence of recycling blocker monensin the three tested agonists revealed similar receptor desensitization after 1 h of agonist treatment. This strongly supports the idea that differences in the agonist-induced receptor desensitization might be due to differences in the ability of agonists to mediate receptor endocytosis and recycling.
Role of receptor endocytosis in the compensatory upregulation of the cAMP-pathway after prolonged agonist treatment: The finding that agonists with high efficacies in inducing receptor endocytosis revealed only weak receptor desensitization led us to propose that prolonged signaling caused by receptor endocytosis and recycling should facilitate the compensatory development of adenylate cyclase superactivation. Therefore, the effect of incubation with DAMGO and morphine for 1 h and 8 h on the cAMP accumulation in HEK293 cells was examined. Pretreatment for 1 h with DAMGO or morphine did not result in a detectable cAMP superactivation (Fig. 5A). However, treatment with morphine for 8 h resulted in a ~4-fold cAMP superactivation, whereas 8 h-treatment with the receptor-internalizing agonist DAMGO resulted in a ~5-6-fold cAMP superactivation (Fig. 5A). Since both agonists showed similar signaling efficacies and potencies (table 1), we speculated that the observed variations in the cAMP accumulation after chronic agonist treatment might be affected by differences in the efficacies of DAMGO and morphine to induce receptor endocytosis and recycling. To further analyze the role of receptor endocytosis and recycling in the process of cAMP accumulation, MOR1 expressing cells were treated with DAMGO in the presence or absence of the recycling blocker monensin for 8 h. Fig. 5B shows that in the presence of the recycling blocker monensin, the DAMGO-induced cAMP accumulation was significantly decreased compared to cells treated with DAMGO alone. Moreover, the morphine-induced cAMP accumulation was not affected by the coapplication of monensin (Fig. 5B). Recently a splice variant of the mouse µ-opioid receptor (MOR1D) has been identified which undergoes receptor endocytosis and recycling after morphine treatment (Koch et al., 2001; Pan et al., 1999). We therefore tested whether MOR1 and MOR1D differ in the cAMP accumulation after morphine treatment. As depicted in Fig. 5C the internalizing receptor splice variant MOR1D revealed a higher
cAMP accumulation after 8 h of morphine treatment compared to MOR1, which is not internalized by morphine treatment. These results strongly confirm our hypothesis of a maintenance of receptor signaling by receptor endocytosis and recycling resulting in an upregulation of the cAMP pathway during chronic agonist treatment.
Discussion

Chronic opioid treatment results in the development of tolerance reducing the responsiveness to the agonist. The mechanisms involved in the development and regulation of opioid tolerance are multifaceted. After chronic opioid treatment the µ-opioid receptor undergoes fast receptor phosphorylation and uncoupling, followed by receptor internalization. Both, the µ-opioid receptor desensitization and the subsequent receptor internalization have long been considered to directly contribute to the development of opioid tolerance by reducing the number of signaling receptors. In contrast to this hypothesis, recent studies have demonstrated that agonist-induced µ-opioid receptor internalization plays an important role in reducing the development of opioid tolerance after chronic agonist-treatment (Finn and Whistler, 2001; Koch et al., 2001; Koch et al., 1998; Whistler et al., 1999; Williams et al., 2001). Remarkably, it has recently been reported that the coapplication of a low dose of the receptor-internalizing drug DAMGO can facilitate the morphine-induced endocytosis of oligomeric µ-opioid receptor complexes and thus prevents morphine tolerance in rats (He et al., 2002). This finding prompted us to investigate whether a combination of morphine with clinically important receptor-internalizing opioids might be relevant for analgesic therapy in reducing morphine tolerance. We therefore determined the endocytotic efficacies and potencies of a series of clinically relevant opioids and tested the effect of a coapplication of these agonists on morphine-induced receptor internalization. To
further investigate the effect of endogenous expressed opioids on the morphine-induced internalization we included β-endorphin in our test. When various concentrations of the receptor-internalizing agonists etonitazene, sufentanil, β-endorphin, piritramide, or methadone were coapplied with morphine, we observed an increase in receptor endocytosis compared to morphine alone, but this effect was less than that induced by the tested receptor-internalizing agonists alone. Indeed, in our coapplication test morphine acted as a partial agonist and inhibited the receptor endocytosis induced by all tested agonists. Moreover, others (Bailey et al., 2003) and we failed to detect a facilitating effect of DAMGO on the morphine-induced receptor endocytosis in HEK293 cells as published by He et al. (He et al., 2002). Thus, the mechanistic basis for the reduction of morphine-induced tolerance in rats by coapplication of a low dose of DAMGO remains unknown.

In addition, it is still unresolved by which mechanism receptor endocytosis reduces the development of opioid tolerance. The RAVE (receptor activity versus endocytosis) model suggests that receptor endocytosis results in a fast uncoupling and termination of receptor-signalling reducing cellular adaptive changes that add to development of opioid tolerance (Whistler and von Zastrow, 1999). However, recent publications demonstrated that μ-opioid receptors undergo fast receptor recycling and reactivation after endocytosis (Ferguson, 2001; Koch et al., 2001; Koch et al., 1998; Law et al., 2000) and that receptor uncoupling and internalization as well as opioid tolerance and the upregulation of adenylate cyclase activity are dissociable phenomena (Bohn et al., 2000; Bohn et al., 1999; Celver et al., 2004). Moreover, our present finding that the endocytotic efficacies of opioids are negatively correlated with the development of receptor desensitization argues against a fast receptor uncoupling after endocytosis. Here we provide evidence that agonists with low endocytotic efficacies like buprenorphine, pethidine, or morphine showed faster receptor desensitization than receptor-
internalizing agonists. In our experiments receptor desensitization was defined as the decrease in receptor signaling, measured by inhibition of adenylate cyclase, after chronic agonist treatment and therefore represents both, signaling lost by receptor uncoupling and signaling lost by internalization prior to recycling of the reactivated receptor. Both are separable events and affect the receptor signaling to transduction systems. However, the fast receptor desensitization of µ-agonists with low endocytotic efficacies reveals that receptor desensitization is mediated primarily by receptor phosphorylation and uncoupling and does not require receptor internalization. In fact the reduced desensitization of agonists with high endocytotic potencies indicate that receptor internalization represents an important mechanism for the recycling and reactivation rather than for the deactivation of the µ-opioid receptor signaling. This is further supported by our finding that blocking of receptor recycling by monensin led to acceleration of receptor desensitization after treatment with receptor-internalizing agonists.

However, there is still confusion about the ability of morphine to induce receptor desensitization because some studies have shown receptor desensitization by morphine (Borgland et al., 2003; Koch et al., 2004; Koch et al., 2001) whereas, other reports claim that morphine is incapable of producing µ-opioid receptor desensitization (Alvarez et al., 2002; Bailey et al., 2003; Whistler and von Zastrow, 1999). This discrepancy could stem from differences in the methods of desensitization measurement and from the different cell systems used in these assays. In most of the studies where no receptor desensitization after morphine treatment was observed, desensitization was determined by measuring changes in the K⁺ or Ca⁺ conductance or in cAMP-inhibition within minutes of exposure to the agonists. Since morphine-activated µ-opioid receptors are known to be a poor substrate for GRK2 phosphorylation (Koch et al., 2001; Whistler and von Zastrow, 1998) short term incubations might not be sufficient for
inducing morphine-mediated receptor phosphorylation and desensitization. This suggestion is supported by our recent finding that incubation with morphine results in a delayed but persistent µ-opioid receptor phosphorylation and desensitization (Schulz et al., 2004). Thus, it is reasonable to speculate that the observed morphine-induced receptor desensitization after long term incubation (≥1 h) might be due to an accumulation of phosphorylated and desensitized µ-opioid receptors in the plasma membrane.

Chronic opioid treatment of µ-opioid receptor expressing cells in culture produces a compensatory upregulation of the cAMP pathway (Avidor-Reiss et al., 1995). To rule out that the decreased receptor activity observed after chronic morphine treatment is simply due to an adaptive upregulation of the adenylate cyclase activity, we tested the effect of chronic morphine and DAMGO treatment on the cAMP accumulation in HEK293 cells after agonist withdrawal. In HEK293 cells after 1 h of DAMGO or morphine treatment no significant increase in the cAMP upregulation could be detected (Fig. 4A) indicating that compensatory cAMP upregulation is not involved in the observed decrease of receptor activity. However, after 8 h of agonist treatment marked cAMP accumulation was observed for both DAMGO and morphine after withdrawal. Remarkably, treatment of HEK293 cells with the receptor-internalizing agonist DAMGO for 8 h resulted in a significantly higher cAMP accumulation compared to the non-internalizing agonist morphine. In addition blocking of receptor recycling in DAMGO pretreated cells by monensin led to a decrease of the cAMP accumulation. Furthermore, the µ-opioid receptor splice variant MOR1D which undergoes endocytosis after morphine treatment (Koch et al., 2001) showed a higher cAMP accumulation after morphine-treatment than the non-internalizing MOR1 wildtype receptor. These results indicate that the decrease in the receptor activity after morphine treatment is due to receptor desensitization and not
to a compensatory upregulation of the adenylate cyclase activity as suggested by the RAVE model (Finn and Whistler, 2001). In addition these data clearly show that prolonged receptor signaling mediated by receptor endocytosis and recycling/reactivation might reduce the development of tolerance but can enhance compensatory mechanisms leading to opioid dependence.

In conclusion, we have used HEK293 cells expressing the rat µ-opioid receptor to gain information about the role of receptor internalization in the development of opioid tolerance and dependence. We have demonstrated that the efficacy of opioids to induce receptor endocytosis is negatively correlated with the development of receptor desensitization. On the other hand, receptor endocytosis was demonstrated to enhance the counterregulatory upregulation of adenylate cyclase activity after chronic opioid treatment, by maintaining the receptor signaling.
Acknowledgements

We thank Evelyn Kahl, Sandra Großeheilmann, and Dirk Franke for excellent technical assistance.
References


receptor internalization: opiate drugs have differential effects on a conserved


Koch, T., Kroslak, T., Mayer, P., Raulf, E. and Höllt, V. (1997) Site mutation in
the rat mu-opioid receptor demonstrates the involvement of calcium/calmodulin-

Koch, T., Schulz, S., Pfeiffer, M., Klutzny, M., Schröder, H., Kahl, E. and Höllt,
V. (2001) C-terminal splice variants of the mouse mu-opioid receptor differ in


Law, P.Y., Erickson, L.J., El-Kouhen, R., Dicker, L., Solberg, J., Wang, W.,


Footnotes

*This work was supported by HO 1027/10-1 (T.K.), SCHU 924/4-3 (S.S.), SFB 426/A2 (V.H.), from the Deutsche Forschungsgemeinschaft, QRTL-1999-00908 (S.S.) from the European Commission, and Dr. Robert Pfleger foundation (T.K.).
Legends for Figures

Figure 1: Quantitative analysis of agonist-induced MOR1 internalization by ELISA. MOR1-expressing HEK293 cells were treated with the drugs shown for 60 min. The agonist concentrations represent the doses required to induce the maximal effect on receptor endocytosis for each drug. After drug treatment ELISA as described under Materials and Methods quantified the receptor endocytosis. Values are the mean of ± standard error of three to six separate experiments.

Figure 2: Effect of various µ-opioid agonists on morphine-induced µ-opioid receptor internalization. Coapplication of morphine with indicated concentrations of DAMGO (A), etonitazene (B), sufentanil (C), β-endorphin (D), piritramide (E), or methadone (F) did not enhance the µ-opioid receptor endocytosis compared to that induced by the tested agonists alone. Note that, in fact, coapplication of morphine reduced the µ-opioid receptor endocytosis induced by all doses of agonists tested. Values are the mean of ± standard error of three separate experiments.

Figure 3: A: Comparison of MOR1 endocytosis and desensitization in HEK293 cells. For the desensitization experiments MOR1 expressing HEK293 cells were preincubated for 60 min with indicated drugs; each drug concentration was 100 times of it's EC₅₀ for AC-inhibition (Table 1). After washing, cells were treated with 25 µM
forskolin or 25 µM forskolin plus the respective agonist, and cAMP levels were
determined as described under “Materials and Methods”. Maximum agonist-induced
inhibition of cAMP accumulation without agonist preincubation has been defined as
100%. The resulting receptor desensitization data were compared with the data
summarized from all endocytosis experiments (Figure 1). Values are the mean ±
standard error of three to six separate experiments. The percentage of the total MOR
internalized by a given concentration of agonist (taken from Fig.1) was plotted as a
function of amount of desensitization. A significant negative correlation was found
(non-parametric Spearman’s test; r = -0.8595; two-tailed p = 0.0002). B: A
comparison of the internalization/signaling EC50 ratio of opioid agonists and the
receptor desensitization in HEK293 cells. The receptor desensitization data after 1 h
of agonist treatment (Table 1 and Fig. 3) were compared with the
internalization/signaling EC50 ratios (Table 1) of the tested agonists. A significant
correlation was found (non parametric Spearman’s test; r = 0.9739; two-tailed p <
0.0001).

**Figure 4:** Effect of monensin treatment on the agonist-induced µ-opioid
receptor desensitization. For the desensitization experiments MOR1 expressing
HEK293 cells were preincubated for 60 min with indicated agonists with and without
50 µM monensin; each agonist concentration was 100 times of it's EC50 for AC-
inhibition (Table 1). After washing, cells were treated with 25 µM forskolin or 25 µM
forskolin plus the respective agonist, and cAMP levels were determined as described
under “Materials and Methods”. Maximum agonist-induced inhibition of cAMP
accumulation without agonist preincubation has been defined as 100%. Values are
the mean ± standard error of three to six separate experiments. Asterisks indicate
significant difference in agonist-induced receptor desensitization between monensin treated and untreated cells (p<0.05, ANOVA followed by Bonferroni test). Note that for the receptor internalizing drugs DAMGO and methadone, treatment with the recycling blocker monensin resulted in a distinct increase of receptor desensitization. In contrast receptor desensitization after morphine treatment was not affected by coapplication of monensin.

Figure 5: Effect of receptor internalization on the superactivation of cAMP pathway in HEK 293 cells. A: MOR1 expressing cells were treated chronically (1 and 8 h) with 1 µM DAMGO or 1 µM morphine, and superactivation of the cAMP pathway after agonist withdrawal was assessed relative to untreated control cells. Significant upregulation of cAMP pathway was detected after 8 h of agonist treatment, but not after 1 h of agonist treatment. However, 8 h of DAMGO treatment resulted in a higher cAMP upregulation compared to morphine-treated cells. Asterisk indicates significant difference in cAMP superactivation between morphine and DAMGO treated cells (p<0.01, ANOVA followed by Bonferroni test). B: Cells were treated for 8 h with DAMGO or morphine in the presence or absence of 50 µM monensin. After DAMGO withdrawal the monensin pretreated cells revealed a significant lower cAMP upregulation compared to cells only treated with DAMGO. However, monensin treatment had no effect on the morphine-induced cAMP upregulation. Asterisk indicates significant difference in cAMP superactivation between monensin treated and untreated cells after 8 h of DAMGO incubation (p<0.05, ANOVA followed by Bonferroni test). C: MOR1 and MOR1D expressing HEK293 cells were treated with 1 µM morphine for 8 h. Saturation binding experiments revealed no marked differences between MOR1D and MOR1 expressing cells with respect to their number of [³H]
DAMGO binding sites (B_{max}) (847 ± 8 fmol/mg protein and 968 ± 7 fmol/mg protein for MOR1D and MOR1, respectively). Note that after agonist withdrawal MOR1D expressing cells revealed a significantly higher cAMP upregulation than rMOR1 expressing cells. Asterisk indicates significant difference in cAMP superactivation between MOR1 and MOR1D expressing cells after 8 h of morphine treatment (p<0.01, ANOVA followed by Bonferroni test).
Table 1: Potency for opioid agonist stimulation of adenylate cyclase inhibition, induction of internalization and receptor desensitization in MOR1 expressing HEK293 cells. For EC$_{50}$ calculation µ-opioid receptor expressing HEK293 cells were incubated with increasing amounts of agonists (10$^{-13}$ - 10$^{-4}$ M) and adenylate cyclase inhibition and internalization data were analyzed (sigmoidal dose-response curve fit analysis; GraphPad Software Inc., San Diego, CA). RA/VE value was defined as relative activity versus endocytosis. Similar to Whistler et al. (1999), the peptide DAMGO was defined as having activity and endocytosis of 1 und thus a RA/VE of 1. Based on the DAMGO values morphine has a relative activity of 0.98 and a relative endocytosis of 0.1 resulting in a RA/VE of 9.8.

<table>
<thead>
<tr>
<th>Agonist</th>
<th>Endocytosis (%)</th>
<th>AC-Inhibition (%)</th>
<th>RA/VE</th>
<th>AC-Inhibition (nM)</th>
<th>Endocytosis (nM)</th>
<th>Ratio</th>
<th>Desensitization (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine</td>
<td>5 ± 2</td>
<td>64 ± 5</td>
<td>9.8</td>
<td>25 ± 4</td>
<td>&gt; 1mM</td>
<td>&gt;40,000</td>
<td>65 ± 4</td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>7 ± 2</td>
<td>31 ± 7</td>
<td>3.36</td>
<td>36 ± 3</td>
<td>&gt; 1mM</td>
<td>&gt;27,777</td>
<td>69 ± 5</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>7 ± 2</td>
<td>54 ± 4</td>
<td>5.93</td>
<td>84 ± 4</td>
<td>&gt; 1mM</td>
<td>&gt;11,905</td>
<td>55 ± 8</td>
</tr>
<tr>
<td>Pethidine</td>
<td>5 ± 1</td>
<td>62 ± 6</td>
<td>9.5</td>
<td>280 ± 30</td>
<td>&gt; 1mM</td>
<td>&gt;3,571</td>
<td>53 ± 4</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>9 ± 5</td>
<td>59 ± 7</td>
<td>5</td>
<td>290 ± 22</td>
<td>&gt; 1 mM</td>
<td>&gt;3,448</td>
<td>46 ± 3</td>
</tr>
<tr>
<td>Nortilidine</td>
<td>6 ± 3</td>
<td>63 ± 8</td>
<td>8.1</td>
<td>370 ± 41</td>
<td>&gt; 1mM</td>
<td>&gt;2,702</td>
<td>42 ± 5</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>22 ± 6</td>
<td>44 ± 5</td>
<td>1.54</td>
<td>129 ± 53</td>
<td>80,000 ± 10,000</td>
<td>620</td>
<td>41 ± 5</td>
</tr>
<tr>
<td>Methadone</td>
<td>25 ± 3</td>
<td>57 ± 13</td>
<td>1.76</td>
<td>11 ± 6</td>
<td>10,000 ± 2,300</td>
<td>909</td>
<td>43 ± 4</td>
</tr>
<tr>
<td>Piritramide</td>
<td>30 ± 6</td>
<td>60 ± 8</td>
<td>1.54</td>
<td>21 ± 8</td>
<td>1,800 ± 700</td>
<td>86</td>
<td>34 ± 4</td>
</tr>
<tr>
<td>β-Endorphin</td>
<td>32 ± 5</td>
<td>56 ± 5</td>
<td>1.35</td>
<td>13.7 ± 2.5</td>
<td>1,000 ± 269</td>
<td>73</td>
<td>30 ± 4</td>
</tr>
<tr>
<td>DAMGO</td>
<td>50 ± 5</td>
<td>65 ± 7</td>
<td>1</td>
<td>13 ± 3</td>
<td>600 ± 123</td>
<td>46</td>
<td>25 ± 3</td>
</tr>
<tr>
<td>Sufentanil</td>
<td>48 ± 7</td>
<td>70 ± 7</td>
<td>1.12</td>
<td>0.055 ± 0.03</td>
<td>0.9 ± 0.32</td>
<td>16.4</td>
<td>15 ± 2</td>
</tr>
<tr>
<td>Etonitazene</td>
<td>47 ± 4</td>
<td>72 ± 3</td>
<td>1.18</td>
<td>1.9 ± 0.6</td>
<td>0.7 ± 0.35</td>
<td>0.37</td>
<td>10 ± 4</td>
</tr>
</tbody>
</table>
Figure 1

![Graph showing agonist-induced receptor internalization](image-url)

- 10µM Morphine
- 10µM Nortilidine
- 10µM Pethidine
- 10µM Buprenorphine
- 10µM Hydromorphone
- 10µM Oxycodone
- 10µM Fentanyl
- 10µM Methadone
- 10µM Piritramide
- 10µM β-Endorphin
- 10nM Sufentanil
- 10nM Etonizazene
- 1µM DAMGO

Maximum agonist-induced receptor internalization (%)
Figure 2

A

- 1μM Morphine
- DAMGO
- DAMGO + 1μM Morphine

% receptor endocytosis

- 1nM
- 10nM
- 0.1μM
- 1μM

DAMGO

B

- 1μM Morphine
- Etonitazene
- Etonitazene + 1μM Morphine

% receptor endocytosis

- 0.1nM
- 1nM
- 10nM

Etonitazene

C

- 1μM Morphine
- Sufentanil
- Sufentanil + 1μM Morphine

% receptor endocytosis

- 0.1nM
- 1nM
- 10nM

Sufentanil

D

- 1μM Morphine
- ß-Endorphin
- ß-Endorphin + 1μM Morphine

% receptor endocytosis

- 100nM
- 1μM
- 10μM

ß-Endorphin

E

- 1μM Morphine
- Piriramide
- Piriramide + 1μM Morphine

% receptor endocytosis

- 1μM
- 10μM
- 100μM

Piriramide

F

- 1μM Morphine
- Methadone
- Methadone + 1μM Morphine

% receptor endocytosis

- 1μM
- 10μM
- 100μM

Methadone
Figure 3

A

Maximum receptor endocytosis (% of control)

% receptor desensitization

B

log (internalization/signaling potency ratio)

% receptor desensitization

- Buprenorphine
- Morphine
- Hydromorphone
- Nortilidine
- Oxycodone
- Pethidine
- Fentanyl
- Methadone
- Piritramide
- β-Endorphin
- DAMGO
- Sufentanil
- Etonitazene
Figure 4

The bar chart shows the percentage of receptor desensitization for DAMGO, Methadone, and Morphine. The data is contrasted between experiments performed without Monensin (white bars) and with Monensin (black bars). The asterisks indicate statistically significant differences between the two conditions.